Description
GDC-0349 is an ATP-competitive inhibitor of mTOR that exhibits anticancer chemotherpeutic activity. GDC-0349 displays pre-clinical efficacy in vitro and in vivo.
Product Unit Size | Cost | Quantity | Stock |
---|
GDC-0349 is an ATP-competitive inhibitor of mTOR that exhibits anticancer chemotherpeutic activity. GDC-0349 displays pre-clinical efficacy in vitro and in vivo.
Cas No. | 1207360-89-1 |
---|---|
Purity | ≥98% |
Formula | C24H32N6O3 |
Formula Wt. | 452.55 |
Chemical Name | 1-ethyl-3-[4-[4-[(3S)-3-methylmorpholin-4-yl]-7-(oxetan-3-yl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2-yl]phenyl]urea |
IUPAC Name | 1-ethyl-3-[4-[4-[(3S)-3-methylmorpholin-4-yl]-7-(oxetan-3-yl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2-yl]phenyl]urea |
Synonym | GDC0349 |
Solubility | DMSO 91 mg/mL (201.08 mM) Ethanol 6 mg/mL (13.25 mM) Water Insoluble |
Appearance | Tan to yellow solid |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
MSDS | |
---|---|
Info Sheet | |
Brochures |
Pei Z, Blackwood E, Liu L, et al. Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349. ACS Med Chem Lett. 2012 Nov 29;4(1):103-7. PMID: 24900569.
Serum response factor inhibitor and MRTF-A bind...
Iron chelator.
Synthetic prednisolone prodrug; glucocorticoid ...
Coumarin, more potent isomer; VKORC1 inhibitor....
Histamine H1 antagonist.
Benzazepine derivative; D1 partial agonist, pot...
NSAID; COX-1/2 inhibitor.
p110α PI3K and mTOR inhibitor.
Folic acid derivative
Synthetic cytokinin, plant growth regulator; fi...
S-adenosylmethionine nucleoside analog; methylt...
Inhibitor of EGFR.
p110β PI3K inhibitor.
EGFR inhibitor.
TRPM8 activator, TRPV3 blocker.
Fluoroquinolone; bacterial DNA gyrase inhibitor...
pan-PI3K inhibitor.
Apoptosis inducing agent.
Mycotoxin produced by Fusarium; sphingosine acy...
Inhibitor of CDK.